(INNS)
BAFISONTAMAB(INNC)
IMMUNOGLOBULIN G1-KAPPA-FAB, ANTI-[HOMO SAPIENS MET (MET PROTOONCOGENE RECEPTOR TYROSINE KINASE, HGFR, RCCP2, DFNB97)] AND ANTI-[HOMO SAPIENS EGFR (EPIDERMAL GROWTH FACTOR RECEPTOR, RECEPTOR TYROSINE-PROTEIN KINASE ERBB-1, ERBB1, HER1, HER-1, ERBB)], HOMO SAPIENS AND HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC; KAPPA LIGHT CHAIN AND GAMMA1 HEAVY CHAIN HOMO SAPIENS AND HUMANIZED ANTI-MET AND ANTI-EGFR (V-KAPPA-C-KAPPA-VH-CH1-H- CH2-CH3) (1-663) [V-KAPPA HOMO SAPIENS ANTI-MET (HOMO SAPIENS IGKV1-12*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27- 32.50-52.89-97)) (1-107) -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (153), V101 (191) (108-214) -VH HUMANIZED ANTI-EGFR (HOMO SAPIENS IGHV4-61*01 (89.9%) -(IGHD) -IGHJ3*02 (100%), CDRIMGT [10.7.11] (240-249.267-273.312-322)) (215-333) -HOMO SAPIENS IGHG1*03V G1M3>G1M17, NG1M1 (CH1 R120>K (430) (334-431), HINGE 1-15 (432-446), CH2 (447-556), CH3 E12 (572), M14 (574) (557-661), CHS (662-663)) (334-663)]...; PROPOSED INN: LIST 125, REC. INN: LIST 87(WHO)
BAFISONTAMABUM(INN)